PLEASANTON, Calif., FRAMINGHAM, Mass. and SYDNEY, July 29 /PRNewswire-FirstCall/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, and HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), which develops and manufactures miniaturized implantable heart pumps, announced today that the United States Federal Trade Commission ("FTC") has informed them that the FTC will file a complaint in U.S. Federal District Court to challenge Thoratec's proposed acquisition of HeartWare International.
Thoratec and HeartWare International are disappointed with the FTC's decision to challenge the acquisition. The companies intend to review the FTC's decision and mutually assess the appropriate next steps and promptly communicate their intentions once a decision has been made.
About Thoratec Corporation
Thoratec Corporation is a world leader in therapies to address advanced-stage heart failure. The company's product lines include the Thoratec(R) VAD (Ventricular Assist Device) and HeartMate LVAS, with more than 13,000 devices implanted in patients suffering from heart failure. Additionally, its International Technidyne Corporation (ITC) division is a leader in point-of-care blood testing and skin incision products. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's web sites athttp://www.thoratec.com orhttp://www.itcmed.com.
Thoratec, the Thoratec logo, HeartMate and HeartMate II are registered trademarks of Thoratec Corporation, and IVAD i
|SOURCE Thoratec Corporation|
Copyright©2009 PR Newswire.
All rights reserved